Trajectories of Kidney Function Decline in the 2 Years Before Initiation of Long-term Dialysis

Department of Medicine, VA Puget Sound Healthcare System and University of Washington, Seattle, WA 98108, USA.
American Journal of Kidney Diseases (Impact Factor: 5.76). 02/2012; 59(4):513-22. DOI: 10.1053/j.ajkd.2011.11.044
Source: PubMed

ABSTRACT Little is known about patterns of kidney function decline leading up to the initiation of long-term dialysis.
Retrospective cohort study.
5,606 Veterans Affairs patients who initiated long-term dialysis in 2001-2003.
Trajectory of estimated glomerular filtration rate (eGFR) during the 2-year period before initiation of long-term dialysis.
Patient characteristics and care practices before and at the time of dialysis initiation and survival after initiation.
We identified 4 distinct trajectories of eGFR during the 2-year period before dialysis initiation: 62.8% of patients had persistently low level of eGFR < 30 mL/min/1.73 m2 (mean eGFR slope, 7.7 ± 4.7 [SD] mL/min/1.73 m2 per year), 24.6% had progressive loss of eGFR from levels of approximately 30-59 ml/min/1.73 m2 (mean eGFR slope, 16.3 ± 7.6 mL/min/1.73 m2 per year), 9.5% had accelerated loss of eGFR from levels > 60 mL/min/1.73 m2 (mean eGFR slope, 32.3 ± 13.4 mL/min/1.73 m2 per year), and 3.1% experienced catastrophic loss of eGFR from levels > 60 mL/min/1.73 m2 within 6 months or less. Patients with steeper eGFR trajectories were more likely to have been hospitalized and have an inpatient diagnosis of acute kidney injury. They were less likely to have received recommended predialysis care and had a higher risk of death in the first year after dialysis initiation.
There is substantial heterogeneity in patterns of kidney function loss leading up to the initiation of long-term dialysis perhaps calling for a more flexible approach toward preparing for end-stage renal disease.

Download full-text


Available from: Meda E Pavkov, Aug 14, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Planning for renal replacement therapy, such as referral for arteriovenous fistula placement and transplantation, often is guided by level of estimated glomerular filtration rate (eGFR). The use of risk equations might enable more accurate estimation of time to end-stage renal disease (ESRD), thus improving patient care. Study Design Prospective observational study. Setting & Participants 1,094 participants in the African American Study of Kidney Disease and Hypertension (AASK) cohort. Predictor Age, sex, urine protein-creatinine ratio ≥ 1 g/g, APOL1 high-risk status, and 3-year antecedent eGFR decline. Outcome Cumulative incidence of ESRD from 5 different starting points: eGFR of 30 and 15 mL/min/1.73 m2 and 1-year ESRD risk of 5%, 10%, and 20%, estimated by a published 4-variable kidney failure risk equation. Results 566 participants developed eGFR of 30 mL/min/1.73 m2, 244 developed eGFR of 15 mL/min/1.73 m2, and 437, 336, and 259 developed 1-year ESRD risks of 5%, 10%, and 20%, respectively. The 1-year cumulative incidence of ESRD was 4.3% from eGFR of 30 mL/min/1.73 m2, 49.0% from eGFR of 15 mL/min/1.73 m2, 6.7% from 5% ESRD risk, 15.0% from 10% ESRD risk, and 29% from 20% ESRD risk. From eGFR of 30 mL/min/1.73 m2, there were several risk factors that predicted ESRD risk. From eGFR of 15 mL/min/1.73 m2, only level of proteinuria did; median time to ESRD was 9 and 19 months in those with higher and lower proteinuria, respectively. Median times were less variable from corresponding ESRD risk thresholds. For example, median times to ESRD from 20% ESRD risk were 22 and 25 months among those with higher and lower proteinuria, respectively. Limitations Relatively homogeneous population of African Americans with hypertensive kidney disease. Conclusions Results of the present study suggest the potential benefit of incorporating kidney failure risk equations into clinical care, with selection of a specific threshold guided by its intended use.
    American Journal of Kidney Diseases 10/2014; 65(3). DOI:10.1053/j.ajkd.2014.07.026 · 5.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Estimates suggest that one third of United States health care spending results from overuse or misuse of tests, procedures, and therapies. The American Board of Internal Medicine Foundation, in partnership with Consumer Reports, initiated the "Choosing Wisely" campaign to identify areas in patient care and resource use most open to improvement. Nine subspecialty organizations joined the campaign; each organization identified five tests, procedures, or therapies that are overused, are misused, or could potentially lead to harm or unnecessary health care spending. Each of the American Society of Nephrology's (ASN's) 10 advisory groups submitted recommendations for inclusion. The ASN Quality and Patient Safety Task Force selected five recommendations based on relevance and importance to individuals with kidney disease.Recommendations selected were: (1) Do not perform routine cancer screening for dialysis patients with limited life expectancies without signs or symptoms; (2) do not administer erythropoiesis-stimulating agents to CKD patients with hemoglobin levels ≥10 g/dl without symptoms of anemia; (3) avoid nonsteroidal anti-inflammatory drugs in individuals with hypertension, heart failure, or CKD of all causes, including diabetes; (4) do not place peripherally inserted central catheters in stage 3-5 CKD patients without consulting nephrology; (5) do not initiate chronic dialysis without ensuring a shared decision-making process between patients, their families, and their physicians.These five recommendations and supporting evidence give providers information to facilitate prudent care decisions and empower patients to actively participate in critical, honest conversations about their care, potentially reducing unnecessary health care spending and preventing harm.
    Clinical Journal of the American Society of Nephrology 09/2012; 7(10):1664-1672. DOI:10.2215/CJN.04970512 · 5.25 Impact Factor
  • Clinical Journal of the American Society of Nephrology 01/2013; 8(2). DOI:10.2215/CJN.12841212 · 5.25 Impact Factor